This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome.
The objective of this study was to investigate the effects of GH administration on pulmonary function , sleep , behavior , cognition , linear growth velocity , body composition , and resting energy expenditure ( REE ) in children with Prader-Willi syndrome . The study used a 12-month , balanced , r and omized , double-blind , placebo-controlled , cross-over experimental design . Twelve subjects were r and omized to GH ( 0.043 mg/kg x d ) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months . Differences in outcome variables were determined by paired t tests . Peak flow rate , percentage vital capacity , and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention . The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention . Linear growth velocity , REE , and lean mass were higher ( 67 % , 19 % , and 7.6 % , respectively ) , and fat mass and percentage body fat were lower ( 10.3 % and 8.1 % , respectively ) after GH intervention . GH administration did not change mean fasting ghrelin concentration .  GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function .  GH administration did not impact fasting ghrelin concentration
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .